|
EE04748B1
(et)
|
1999-06-21 |
2006-12-15 |
Boehringer Ingelheim Pharma Kg |
Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
|
|
GB0011903D0
(en)
*
|
2000-05-18 |
2000-07-05 |
Astrazeneca Ab |
Combination chemotherapy
|
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
US6861422B2
(en)
*
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
|
US20050043233A1
(en)
*
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
DE10349113A1
(de)
*
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
|
US20050096332A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Boehringer Ingelheim International Gmbh |
Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
|
|
DE102004029784A1
(de)
*
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
|
DE102004033670A1
(de)
*
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
|
US20060035903A1
(en)
*
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
|
US7759485B2
(en)
*
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
US7728134B2
(en)
*
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
|
US20060074088A1
(en)
*
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
|
EP1632493A1
(de)
*
|
2004-08-25 |
2006-03-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
EP1630163A1
(de)
*
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
CZ2004964A3
(cs)
*
|
2004-09-14 |
2006-03-15 |
Pliva-Lachema A. S. |
Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
|
|
DE102004058337A1
(de)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
|
MX2007009317A
(es)
|
2005-02-03 |
2008-01-30 |
Gen Hospital Corp |
Metodo para tratar cancer resistente a gefitinib.
|
|
CN103110948A
(zh)
|
2005-11-04 |
2013-05-22 |
惠氏公司 |
mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
|
|
PL1948180T3
(pl)
*
|
2005-11-11 |
2013-09-30 |
Boehringer Ingelheim Int |
Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
|
|
JP5688877B2
(ja)
*
|
2005-11-11 |
2015-03-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌疾患の治療用キナゾリン誘導体
|
|
ES2397181T3
(es)
*
|
2006-01-26 |
2013-03-05 |
Boehringer Ingelheim International Gmbh |
Procedimiento para preparar derivados de quinazolina sustituida con aminocrotonilamino
|
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
|
WO2007139939A2
(en)
*
|
2006-05-26 |
2007-12-06 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds in combination therapy
|
|
TW200808325A
(en)
*
|
2006-07-06 |
2008-02-16 |
Astrazeneca Ab |
Novel compounds
|
|
ES2385613T3
(es)
*
|
2006-09-18 |
2012-07-27 |
Boehringer Ingelheim International Gmbh |
Método para tratar cánceres que portan mutaciones de EGFR
|
|
MX337906B
(es)
*
|
2006-10-19 |
2016-03-28 |
Signal Pharm Llc |
Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
|
|
US8168662B1
(en)
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8173686B2
(en)
|
2006-11-06 |
2012-05-08 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8168661B2
(en)
*
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8178564B2
(en)
*
|
2006-11-06 |
2012-05-15 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8129387B2
(en)
|
2006-12-14 |
2012-03-06 |
Vertex Pharmaceuticals Incorporated |
Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors
|
|
US20110033528A1
(en)
*
|
2009-08-05 |
2011-02-10 |
Poniard Pharmaceuticals, Inc. |
Stabilized picoplatin oral dosage form
|
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
|
US20100260832A1
(en)
*
|
2007-06-27 |
2010-10-14 |
Poniard Pharmaceuticals, Inc. |
Combination therapy for ovarian cancer
|
|
JP2010533714A
(ja)
*
|
2007-07-16 |
2010-10-28 |
ポニアード ファーマシューティカルズ， インコーポレイテッド |
ピコプラチンのための経口製剤
|
|
CA2695406A1
(en)
*
|
2007-08-03 |
2009-02-12 |
Boehringer Ingelheim International Gmbh |
Crystalline form of a dihydropteridione derivative
|
|
WO2009023846A2
(en)
*
|
2007-08-15 |
2009-02-19 |
The Research Foundation Of State University Of New York |
Methods for heat shock protein dependent cancer treatment
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
AU2016225895B2
(en)
*
|
2007-10-17 |
2018-02-08 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof
|
|
CN101998851A
(zh)
*
|
2008-02-08 |
2011-03-30 |
帕纳德制药公司 |
吡铂和西妥昔单抗治疗结直肠癌的用途
|
|
EP2100894A1
(en)
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
|
AU2015227503B2
(en)
*
|
2008-06-06 |
2017-02-23 |
Boehringer Ingelheim International Gmbh |
Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
|
|
HRP20180709T1
(hr)
*
|
2008-06-06 |
2018-06-15 |
Boehringer Ingelheim International Gmbh |
Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
|
|
MX338047B
(es)
*
|
2008-06-06 |
2016-03-31 |
Boehringer Ingelheim Int |
Combinacion farmaceutica útil para el tratamiento fr enfermedades que involucran proliferación celular, migración o apoptosis de células de mieloma, angiogéneisis o fibrosis.
|
|
UY31867A
(es)
*
|
2008-06-06 |
2010-01-29 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
|
|
US20170065529A1
(en)
|
2015-09-09 |
2017-03-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical dosage form for immediate release of an indolinone derivative
|
|
UA107560C2
(uk)
*
|
2008-06-06 |
2015-01-26 |
|
Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
|
|
WO2010008744A2
(en)
|
2008-06-17 |
2010-01-21 |
Wyeth |
Antineoplastic combinations containing hki-272 and vinorelbine
|
|
CN102076690A
(zh)
|
2008-06-23 |
2011-05-25 |
维泰克斯制药公司 |
蛋白激酶抑制剂
|
|
RU2498804C2
(ru)
|
2008-08-04 |
2013-11-20 |
ВАЙЕТ ЭлЭлСи |
Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
|
|
EP2373309A1
(en)
*
|
2008-11-21 |
2011-10-12 |
Isis Pharmaceuticals, Inc. |
Anticancer combination comprising docetaxel and an antisense oligonucleotide
|
|
WO2010064422A1
(ja)
*
|
2008-12-02 |
2010-06-10 |
静岡県公立大学法人 |
ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法
|
|
JP5992325B2
(ja)
|
2009-04-06 |
2016-09-14 |
ワイス・エルエルシー |
乳癌のための、ネラチニブを活用する治療計画
|
|
KR101224468B1
(ko)
*
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
SI2451445T1
(sl)
|
2009-07-06 |
2019-07-31 |
Boehringer Ingelheim International Gmbh |
Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
|
|
ES2543280T3
(es)
*
|
2009-08-10 |
2015-08-17 |
Board Of Regents, The University Of Texas System |
Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
|
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
|
CN102020643A
(zh)
|
2009-09-22 |
2011-04-20 |
上海恒瑞医药有限公司 |
二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
|
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
|
HRP20171537T1
(hr)
|
2009-11-05 |
2017-12-15 |
Rhizen Pharmaceuticals S.A. |
Novi modulatori benzopiran kinaze
|
|
SG183155A1
(en)
*
|
2010-02-03 |
2012-09-27 |
Signal Pharm Llc |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
WO2011101369A1
(en)
*
|
2010-02-17 |
2011-08-25 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones, method for production and use thereof
|
|
CN103154246B
(zh)
|
2010-05-14 |
2015-11-25 |
达那-法伯癌症研究所 |
用于治疗白血病的组合物和方法
|
|
CN102985111B
(zh)
*
|
2010-05-14 |
2014-05-07 |
香港大学 |
Gep抗体及其用途
|
|
US9301962B2
(en)
|
2010-05-14 |
2016-04-05 |
Baylor College Of Medicine |
Male contraceptive compositions and methods of use
|
|
BR122014024883A2
(pt)
|
2010-05-14 |
2019-08-20 |
Dana-Farber Cancer Institute, Inc. |
Compostos no tratamento de neoplasia
|
|
SG186885A1
(en)
|
2010-06-04 |
2013-02-28 |
Albany Molecular Res Inc |
Glycine transporter-1 inhibitors, methods of making them, and uses thereof
|
|
US20130289056A1
(en)
|
2010-08-26 |
2013-10-31 |
Boehringer Ingelheim International Gmbh |
Methods of administering an egfr inhibitor
|
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
|
WO2012079075A1
(en)
|
2010-12-10 |
2012-06-14 |
Concert Pharmaceuticals, Inc. |
Deuterated phthalimide derivatives
|
|
EP2678342B1
(en)
|
2011-02-25 |
2015-01-07 |
Takeda Pharmaceutical Company Limited |
N-substituted oxazinopteridines and oxazinopteridinones
|
|
BR112013027774B1
(pt)
|
2011-05-04 |
2020-11-17 |
Rhizen Pharmaceuticals S.A. |
composto e composição farmacêutica
|
|
US20130131069A1
(en)
*
|
2011-05-13 |
2013-05-23 |
Boehringer Ingelheim International Gmbh |
Method for treatment of solid malignancies including advanced or metastatic solid malignancies
|
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
|
US8828391B2
(en)
|
2011-05-17 |
2014-09-09 |
Boehringer Ingelheim International Gmbh |
Method for EGFR directed combination treatment of non-small cell lung cancer
|
|
WO2013130849A1
(en)
|
2012-02-29 |
2013-09-06 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
WO2013159026A1
(en)
|
2012-04-20 |
2013-10-24 |
Concert Pharmaceuticals, Inc. |
Deuterated rigosertib
|
|
ES2647416T3
(es)
|
2012-07-04 |
2017-12-21 |
Rhizen Pharmaceuticals S.A. |
Inhibidores de PI3K delta selectivos
|
|
WO2014012859A1
(en)
|
2012-07-19 |
2014-01-23 |
Boehringer Ingelheim International Gmbh |
Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
|
|
CN116271053A
(zh)
*
|
2012-08-13 |
2023-06-23 |
洛克菲勒大学 |
治疗和诊断黑素瘤
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
EP2922838B1
(en)
|
2012-10-22 |
2018-03-14 |
Concert Pharmaceuticals Inc. |
Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
|
|
WO2014110322A2
(en)
|
2013-01-11 |
2014-07-17 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
WO2014159392A1
(en)
|
2013-03-14 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
KR102240356B1
(ko)
|
2013-04-17 |
2021-04-14 |
시그날 파마소티칼 엘엘씨 |
Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
|
|
CN105377260B
(zh)
|
2013-04-17 |
2020-06-12 |
西格诺药品有限公司 |
二氢吡嗪并-吡嗪类化合物在制备治疗癌症的药物中的应用
|
|
KR102271344B1
(ko)
|
2013-04-17 |
2021-07-01 |
시그날 파마소티칼 엘엘씨 |
디하이드로피라지노-피라진을 사용한 암의 치료
|
|
BR112015026021A2
(pt)
|
2013-04-17 |
2017-07-25 |
Signal Pharm Llc |
terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
|
|
JP6382947B2
(ja)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ，エルエルシー |
前立腺癌を治療するためのジヒドロピラジノ−ピラジン化合物及びアンドロゲン受容体アンタゴニストを含む組合せ療法
|
|
ES2744198T3
(es)
|
2013-04-17 |
2020-02-24 |
Signal Pharm Llc |
Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona
|
|
CN105392499B
(zh)
|
2013-04-17 |
2018-07-24 |
西格诺药品有限公司 |
用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
|
|
WO2014193912A1
(en)
|
2013-05-29 |
2014-12-04 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
EP3024327B1
(en)
|
2013-07-25 |
2019-09-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
|
WO2015011235A1
(en)
*
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii
|
|
CA2919294A1
(en)
*
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Volasertib in combination with decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii
|
|
JP2016525532A
(ja)
|
2013-07-26 |
2016-08-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
骨髄異形成症候群の処置
|
|
EP3066101B1
(en)
|
2013-11-08 |
2020-07-29 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
WO2015106012A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
|
WO2015117087A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
WO2015117055A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
|
WO2015117083A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
|
RU2016134947A
(ru)
|
2014-01-31 |
2018-03-01 |
Дана-Фарбер Кансер Институт, Инк. |
Производные диаминопиримидин бензолсульфона и их применение
|
|
MX377534B
(es)
|
2014-02-28 |
2025-03-10 |
Tensha Therapeutics Inc |
Compuestos para usarse en el tratamiento de hiperinsulinemia.
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
WO2015160880A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
MX2017001757A
(es)
|
2014-08-08 |
2017-05-30 |
Dana Farber Cancer Inst Inc |
Derivados de dihidropteridinona y sus usos.
|
|
WO2016022902A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
|
US10124009B2
(en)
|
2014-10-27 |
2018-11-13 |
Tensha Therapeutics, Inc. |
Bromodomain inhibitors
|
|
PT3214081T
(pt)
|
2014-10-30 |
2020-08-31 |
Kangpu Biopharmaceuticals Ltd |
Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização
|
|
CN106279173A
(zh)
*
|
2015-05-29 |
2017-01-04 |
华东理工大学 |
蝶啶酮衍生物作为egfr抑制剂的应用
|
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
CR20180199A
(es)
|
2015-09-11 |
2018-05-25 |
Dana Farber Cancer Inst Inc |
Acetamida tienotriazolodiazepinas y usos de las mismas
|
|
BR112018004618A2
(pt)
|
2015-09-11 |
2018-09-25 |
Dana-Farber Cancer Institute, Inc. |
ciano tienotriazoldiazepinas e usos das mesmas
|
|
BR112018009798A8
(pt)
|
2015-11-25 |
2019-02-26 |
Dana Farber Cancer Inst Inc |
inibidores de bromodomínio bivalentes e usos dos mesmos
|
|
DE102017005089A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
|
|
DE102017005091A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
|
|
CN106831765B
(zh)
*
|
2016-12-28 |
2018-12-14 |
郑州大学 |
2-(2,6-二氰基苯基)咪唑并[1,2-α]吡啶类化合物及其制备方法
|
|
WO2018157779A1
(zh)
|
2017-02-28 |
2018-09-07 |
康朴生物医药技术（上海）有限公司 |
一种新的异二氢吲哚衍生物、其药物组合物及应用
|
|
EP3624786B1
(en)
|
2017-05-16 |
2023-07-05 |
Ability Pharmaceuticals S.L. |
A pharmaceutical combination for the treatment of a cancer
|
|
EA202090103A1
(ru)
|
2017-06-22 |
2020-04-24 |
Селджин Корпорейшн |
Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b
|
|
CN109776788B
(zh)
*
|
2017-11-14 |
2021-07-30 |
博瑞生物医药（苏州）股份有限公司 |
叶酸受体靶向多臂偶联物
|
|
US20210038602A1
(en)
|
2018-01-25 |
2021-02-11 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia
|
|
CA3097774A1
(en)
*
|
2018-04-24 |
2019-10-31 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
|
US11773096B2
(en)
*
|
2018-08-10 |
2023-10-03 |
Yale University |
Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same
|
|
AU2019392231B2
(en)
|
2018-12-06 |
2022-10-20 |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
|
|
JOP20210298A1
(ar)
|
2019-05-14 |
2023-01-30 |
Provention Bio Inc |
طرق وتركيبات للوقاية من مرض السكري من النوع الأول
|
|
CN110156700A
(zh)
*
|
2019-06-05 |
2019-08-23 |
鲁南制药集团股份有限公司 |
吉非替尼与水杨酸共晶体
|
|
EP4073025B1
(en)
|
2019-12-13 |
2024-03-27 |
Inspirna, Inc. |
Metal salts and uses thereof
|
|
KR20230092863A
(ko)
|
2020-06-11 |
2023-06-26 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
|
WO2025228947A1
(en)
|
2024-04-30 |
2025-11-06 |
Crossfire Oncology B.V. |
Bifunctional compounds capable of inducing degradation of polo-like kinase1
|